Claim Missing Document
Check
Articles

Found 12 Documents
Search

Evaluation of the Effectiveness of Soil-Derived Bacillus sp. as an Entomopathogenic Agent Against Aedes aegypti Larvae Ichwan Baihaki; Afifa Radhina; Herera Rahajeng; Niken Rahmah Ghanny; Fransiskus Samuel Renaldi
ANTHOR: Education and Learning Journal Vol 5 No 5 (2026): Anthor 2026
Publisher : Institut Teknologi Pendidikan Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31004/anthor.v5i5.1446

Abstract

Introduction: Dengue fever (DF) cases frequently emerge during transitional seasons, such as the current period. Vector control programs for dengue fever commonly rely on chemical methods, which may cause adverse environmental impacts. Recently, environmentally friendly approaches using locally derived bacterial strains have been developed for dengue vector control. Methods: This study aimed to evaluate the effectiveness of Bacillus sp. isolated from soil surrounding the campus as an entomopathogenic agent against Aedes aegypti larvae. This research was conducted as a laboratory experimental study, with Bacillus sp. bacteria serving as the subjects to test their pathogenicity against Aedes aegypti larvae. Results and discussion: The results showed that all bacterial isolates resembled Bacillus sp. Among them, isolate B2, obtained from soil under a banyan tree, exhibited the highest larvicidal activity against Aedes aegypti larvae, with a pathogenicity rate of 13.3%, while isolates A1 and C2 showed the lowest activity, with pathogenicity rates of 4.0%. Conclusion: The study concluded that none of the Bacillus sp. isolates were effective as entomopathogenic agents against Aedes aegypti larvae, as all larval mortality percentages were below 50%. Further research is recommended to identify Bacillus sp. isolates with higher entomopathogenic efficacy against Aedes aegypti larvae. This could be achieved through broader soil sampling, a larger number of isolates, and extended study durations.
Endemic Dengue In Indonesia: The Role of Candidate Antivirals And Immunomodulators on Clinical Outcomes and Immune Responses: Ichwan Baihaki; Niken Rahmah Ghanny; Herera Rahajeng; Afifa Radhina; Assyafiya Salwa; Bunga Anggreini Sari
Anakes : Jurnal Ilmiah Analis Kesehatan Vol. 12 No. 2 (2026): ANAKES: Jurnal Ilmiah Analis Kesehatan
Publisher : Universitas Mohammad Husni Thamrin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37012/anakes.v12i2.3244

Abstract

Endemic dengue in Indonesia remains a major public health challenge, with over 250,000 reported cases and more than 1,400 deaths in 2024, placing the country among the highest-burden nations in Southeast Asia. Clinical management is dominated by supportive care, and no specific antiviral agent is currently recommended for routine use in major guidelines. Recent advances in understanding dengue pathogenesis, particularly the interaction between viral replication and host immune responses, have stimulated development of candidate antivirals and immunomodulatory or platelet‑enhancing therapies aimed at reducing disease severity and mortality. This narrative review synthesises data from 1 January 2020 to 7 October 2025 on the effects of these interventions on clinical outcomes (duration of fever, length of hospital stay, progression to severe dengue, mortality) and immunological parameters (viremia, NS1 clearance, cytokine profiles, platelet indices), with emphasis on studies from endemic settings, including Indonesia. Electronic searches of major biomedical databases identified clinical trials, observational studies and preclinical studies reporting relevant outcomes. Overall, candidate antivirals such as celgosivir, ivermectin and newer niclosamide formulations show modest, inconsistent reductions in viremia without clear benefit in hard clinical endpoints. In contrast, several immunomodulators and platelet‑enhancing agents, including rupatadine, recombinant interleukin‑11, anti‑D, eltrombopag and Carica papaya preparations, demonstrate improved platelet counts and some surrogate outcomes, although evidence is heterogeneous and largely derived from small studies with non‑standardised endpoints. A recently proposed core outcome measurement set for dengue treatment trials provides a framework to harmonise outcome selection and assessment, and will be crucial for defining the future role of antivirals and immunomodulators in reducing the burden of endemic dengue.